Blood pressure-lowering efficacy of amiloride versus enalapril as add-on drugs in patients with uncontrolled blood pressure receiving hydrochlorothiazide

Clinical and Experimental Hypertension

Volumn 30, Issue 7, 2008, Pages 553-564

  Guerrero, Patrícia ^a,b   Fuchs, Flávio D ^a,c   Moreira, Leila M ^c   Martins, Vítor M ^c   Bertoluci, Carolina ^c   Fuchs, Sandra C ^a   Gus, Miguel ^a,c  

^a FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^b UNIVERSIDADE ESTADUAL DO OESTE DO PARANÁ   (Brazil)

^c HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

Author keywords

Ambulatory blood pressure monitoring; Amiloride; Enalapril; Hypertension; Pharmacological treatment

Indexed keywords

AMILORIDE; ENALAPRIL; HYDROCHLOROTHIAZIDE; POTASSIUM; PROPRANOLOL;

ADD ON THERAPY; ADULT; AGED; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE MONITORING; BLOOD PRESSURE REGULATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DIASTOLIC BLOOD PRESSURE; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; HEADACHE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MUSCLE CRAMP; PATIENT COMPLIANCE; POTASSIUM BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; SEXUAL DYSFUNCTION; SYSTOLIC BLOOD PRESSURE; TREATMENT OUTCOME;

AGED; AMILORIDE; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; BLOOD PRESSURE MONITORING, AMBULATORY; DIURETICS; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; ENALAPRIL; FEMALE; HUMANS; HYDROCHLOROTHIAZIDE; HYPERTENSION; MALE; MIDDLE AGED; SODIUM CHANNEL BLOCKERS;

EID: 54049121400     PISSN: 10641963     EISSN: 15256006     Source Type: Journal    
DOI: 10.1080/10641960802441906     Document Type: Article

References (35)

1. Fuchs FD, Guerrero P, Gus M. What is next when the first blood pressure-lowering drug is not sufficient? Expert Rev Cardiovasc Ther. 2007;5:435-439.
2. PROGRESS Collaborative Group. Randomized trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack. Lancet. 2001;358:1033-1041.
3. Veterans Administration Cooperative Study Group on Antihypertensive Agents. Effects of treatment on morbidity in hypertension: Results in patients with diastolic blood pressures averaging 115 through 129 mmHg. JAMA. 1967;202:1028-1034.
4. Pepine CJ, Handberg EM, Cooper-Dell, et al. A calcium antagonist vs. a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease - the International Verapamil-Trandolapril Study (INVEST): A randomised controlled trial. JAMA. 2003;290:2805-2816.
5. Dahlöf B, Sever PS, Poulter NR, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipina adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): A multicentre randomized controlled trial. Lancet. 2005;366:895-906.
6. Wassertheil-Smoller S, Psaty B, Greenland P, et al. Association between cardiovascular outcomes and antihypertensive drug treatment in older women. JAMA. 2004;292:2849-2859.
7. The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). 2007 guidelines for the management of arterial hypertension. J Hypertens. 2007;25:1105-1187.
8. Stertiou GS, Makris T, Papavasiliou M, Efstathiou S, Manolis A. Comparison of antihypertensive effects of an angiotensin-converting enzyme inhibitor, a calcium antagonist and a diuretic in patients with hypertension not controlled by angiotensin receptor blocker monotherapy. J Hypertens. 2005;23:883-889.
9. Agrawal R, Marx A, Haller H. Efficacy and safety of lercarnidipine versus hydrochlorothiazide as add-on to enalapril in diabetic populations with uncontrolled hypertension. J Hypertens. 2006;24:185-192.
10. Sierra A, Gil-Extremera B, Calvo C, et al. Comparison of the antihypertensive effects of the fixed dose combination enalapril 10 mg/nitrendipine 20 mg vs. losartan 50 mg/hydrochlorothiazide 12.5 mg, assessed by 24-h ambulatory blood pressure monitoring, in essential hypertensive patients. J Hum Hypertens. 2004;18:215-222.
11. Backhouse CI, Platt J, Crawford RJ, Allman S. An open study to compare the efficacy and tolerability of two diuretic combinations, frusemide plus amiloride and hydrochlorothiazide plus amiloride, in patients with mild to moderate essential hypertension. Curr Med Res Opin. 1988;10:690-698.
12. Rappelli A, Ambrosio GB, Caiazza A, et al. Evaluation of the safety and efficacy of the lisinopril + hydrochlorothiazide and captopril + hydrochlorothiazide combinations in the treatment of essential arterial hypertension. Minerva Med. 1992;83:57-64.
13. Luccioni R, Sever OS, Perri TD, et al. An equivalence study of the safety and efficacy of a fixed-dose combination of perindopril with indapamide versus fixed-dose combinations of captopril with hydrochlorothiazide and enalapril with hydrochlorothiazide in the treatment of hypertension. J Hypertens. 1995;13:1847-1851.
14. Clement J, Schwebig A, Mazaud C, Justal A, Bricaud H. Comparative study of the efficacy and tolerance of capozide and moduretic administered in a single daily dose for the treatment of chronic moderate arterial hypertension. Postgrad Med J. 1986;62 (Suppl. 1):S132-S134.
15. Mammarella A, Paoletti V, Barlattani M, Leone G, Filippello CP, Mariani AR. Efficacy and tolerability of captopril-hydrochlorothiazide vs amiloride-hydrochlorothiazide combination in mild to moderate arterial hypertension. Clin Ter. 1989;129:129-134.
16. Chobanian AV, Bakris GL, Black HR et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC VII). JAMA. 2003;289:2560-2572.
17. Franse LV, Pahor M, Di Bari M, Somes GW, Cushman WC, Applegate WB. Hypokalemia associated with diuretic use and cardiovascular events in the Systolic Hypertension in the Elderly Program. Hypertension. 2000;35:1025-1030.
18. Zillich AJ, Garg J, Basu S, Bakris GL, Carter BL. Thiazide diuretics, potassium, and the development of diabetes: A quantitative review. Hypertension. 2006;48:1-6.
19. MRC Working Party. Medical research council trial of treatment of hypertension in older adults: Principal results. BMJ. 1992;304:405-412.
20. Brown MJ, Palmer CR, Castaigne A, et al. Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a goal in hypertension treatment (INSIGHT). Lancet. 2000;356:366-372.
21. Baker EH, Duggal A, Dong Y, Ireson NJ, Wood M, Markandu ND, MacGregor GA. Amiloride, a specific drug for hypertension in black people with T594M variant? Hypertension. 2002;40:13-17.
22. Lubianca JN, Moreira LB, Gus M, Fuchs FD. Stopping oral contraceptives: An effective blood pressure-lowering intervention in women with hypertension. J Hum Hypertens. 2005;19:451-455.
23. Fuchs FD, Gus M, Moreira LB, Moreira WD, Gonçalves SC, Nunes G. Headache is not more frequent among patients with moderate to severe hypertension. J Hum Hypertens. 2003;17:787-790.
24. Gus M, Fuchs FD, Pimentel M, Rosa D, Melo AG, Moreira LB. Behavior of ambulatory blood pressure surrounding episodes of headache in mildly hypertensive patients. Arch Intern Med. 2001;161:252-255.
25. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clinical Chem. 1972:18:499-502.
26. Granger B, Swedberg K, Ekman I, Granger CB, Olofsson B, McMurray JJV, et al. Adherence to candesartan and placebo and outcomes in chronic heart failure in the CHARM programme: Double-blind, randomized, controlled clinical trial. Lancet. 2005;366:2005-2011.
27. The National Heart, Lung, and Blood Institute Wording Group on Future Directions in Hypertension Treatment Trials. Major clinical trials of hypertension: What should be done next? Hypertension. 2005;46:1-6.
28. Staessen JA, Li Y, Thijs L, Wang JG. Blood pressure reduction and cardiovascular prevention: An update including the 2003-2004 secondary prevention trials. Hypertens Res. 2005;28:385-407.
29. Canessa CM, Schild L, Buell G, Thorens B, Gautschi I, Horisberger JD, et al. Amiloride-sensitive epithelial Na+ channel is made of three homologous subunits. Nature. 1994;367:463-467.
30. Eide IK, Torjesen PA, Drolsum A, Babovic A, Lilldahl NP. Low-renin status in therapy-resistant hypertension: a clue to efficient treatment. J Hypertens. 2004;22:2217-2226.
31. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs. diuretic. JAMA. 2002;288:2981-2997.
32. Krantz MJ, Mehler PS. Angiotensin-converting enzyme inhibitors and diuretics: Optimal combination therapy. Ann Intern Med. 2004;141:893.
33. IV Brazilian Guidelines in Arterial Hypertension Work Groups. IV Brazilian guidelines in arterial hypertension. Arq Bras Cardiol. 2004;82 (Suppl. 4):7-22.
34. Siscovick DS, Raghunathan TE, Psaty BM, Koepsell TD, Wicklund KG, Lins X, et al. Diuretic therapy for hypertension and the risk of primary cardiac arrest. N Engl J Med. 1994;330:1852-1857.
35. Whelton PK, He J, Cutler JA, Brancati FL, Appel LJ, Follmann D, Klag MJ. Effects of oral potassium on blood pressure. Meta-analysis of randomized controlled clinical trials. JAMA 1997;277:1624-1632.